Blueprint Medicines is cutting funding to its clinical-stage CDK2 inhibitor even as the Ayvakit-maker pushes forward with similar preclinical breast cancer-focused therapies. The biopharma has ...
Tyk Medicines Inc. has patented new cyclin-dependent kinase 2 (CDK2) and/or cyclin-dependent kinase 4 (CDK4) inhibitors reported to be useful for the treatment of cancer, infections, metabolic ...
Zacks.com on MSN4mon
Incyte Announces Promising New Data on Oncology Candidate at ESMOIncyte INCY announced new data from a phase I study on pipeline candidate INCB123667 in patients with advanced solid tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback